Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios by Diaf, M et al.
ORIGINAL ARTICLE
Impact of corpulence parameters and haemoglobin
A1c on metabolic control in type 2 diabetic
patients: comparison of apolipoprotein B/A-I
ratio with fasting and postprandial conventional
lipid ratios
Mustapha Diaf*, Boumediene M. Khaled and Fériel Sellam
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Background and objective: The incidence of diabetes co-morbidities could probably be better assessed by
studying its associations with major corpulence parameters and glycaemic control indicators. We assessed the
utility of body mass index (BMI), waist circumference (WC), and glycosylated haemoglobin (HbA1c) levels in
metabolic control for type 2 diabetic patients.
Methods: Fasting and postprandial blood samples were collected from 238 type 2 diabetic patients aged
57.4911.9 years. The sera were analysed for glucose, HbA1c, total cholesterol (TC), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and apolipoproteins
(apoA-I and apoB). Ratios of lipids and apolipoproteins were calculated and their associations with BMI,
WC, and HbA1c levels were analysed.
Results: Our investigation showed increases in most fasting and postprandial lipid parameters according to
BMI and WC. In men, postprandial HDL-c and TG levels were significantly higher (pB0.05) in overweight
and obese patients, respectively, as well as in patients with abdominal obesity. Contrariwise, postprandial TC
levels were significantly higher (pB0.01) in overweight and abdominal obese women. However, elevations
of apoA-I and apoB levels were according to BMI and WC in both genders. There was a strong influence of
BMI, WC, and HbA1c levels on the apoB/apoA-I ratio compared to traditional fasting and postprandial lipid
ratios in both men and women. The apoB/apoA-I ratio was more correlated with postprandial TC/HDL and
LDL-c/HDL-c ratios in men and with postprandial TG/HDL-c in women.
Conclusion: The apoB/apoA-I ratio is helpful in assessing metabolic risk caused by overall obesity, abdominal
obesity and impaired glycaemia in type 2 diabetic patients.
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R
ecent estimates state that the worldwide pre-
valence of type 2 diabetes is increasing and is
likely to affect over 400 million people by 2030.
This rising prevalence of type 2 diabetes is thoroughly
linked to the upsurge in obesity. More than 90% of type
2 diabetes is attributable to excess weight (1).
Measured by body mass index (BMI), obesity is
regarded as a powerful risk factor for type 2 diabetes
and its co-morbidities and has increased clearly during the
past decades. Estimates suggest that obesity will affect up
to 1 billion people in 2030 (2). Although the BMI is one
of the most commonly used indicators of overweight
and obesity, it does not take into account the body fat
pattern (3). Independently from overall obesity, assess-
ment of abdominal obesity by waist circumference (WC)
has been shown to be a strong risk factor for type 2 diabetes
as well. These obesity indicators may vary according to
some factors such as ethnicity, age, and sex (4, 5). Among
Europeans and the white US population, general obesity is
considered as a consistent predictor of diabetes. However,
central obesity has been shown to be a better predictor in
Asian populations (6, 7). In contrast, in 2004, Janssen et al.
(8) showed that obesity-related health risk is explained by
WC and not by BMI.
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Regardless of BMI and WC as powerful indicators of
obesity, assessment of glucose and lipid levels appears
to identify diabetic individuals at increased risk for de-
velopment of cardiovascular diseases (CVD). Glycosy-
lated haemoglobin (HbA1c) is considered as a long-term
marker for blood glucose fluctuations. Elevated HbA1c
is an independent risk factor for coronary heart disease
(CHD) in patients with or without diabetes (9). However,
and contrary to apolipoproteins, studies suggest that lipid
levels may not vary much between the fasting and the
postprandial periods and that the risk of CHD and stroke
is similarly increased for both postprandial and fasting
lipid rates (10).
This study was conducted on patients with type 2
diabetes to evaluate, during both fasting and postpran-
dial states, the impact of overweight/obesity (identified
through BMI), abdominal fat accumulation (measured
by WC), and HbA1c levels (in mmol/mol) on glucose
and lipid blood parameters, and also on dyslipidaemia by
studying the mutual association between traditional lipid
ratios and apolipoproteins ratios.
Patients and methods
Study population
A total of 238 type 2 diabetic patients (86 males and
152 females) were enrolled in this study. Our investigation
lasted 9 months, from March to December 2013, at the
level of the Public Establishment of Local Health Centre
(Diabetes Centre of Ex Gambetta and Mostefa Ben
Brahim Polyclinic) in Sidi-Bel-Abbes city and Meslem
Tayeb Hospital in Mascara city. These two cities are
located in the north-western region of Algeria.
According to data available at the health departments
of these two cities, the approximate number of patients
with type 2 diabetes was about 22,000 (according to the
census of December, 2012), of whom two-thirds were
women and almost 18% were treated solely with oral
anti-diabetic agents.
During periodic medical follow-up sessions and
based on a careful analysis of their medical records, we
randomly solicited type 2 diabetic patients who met the
inclusion criteria, that is, aged between 19 and 75 years,
diabetes duration of less than 15 years, not suffering
from diabetes complications, and exclusively under oral
anti-diabetic treatments. We used the simple random
sampling method without replacement, in which each
individual in the targeted population has the same
probability of being selected.
The mean ages of male and female patients were
56.8913.1 and 57.7911.3 years, respectively. The aver-
age diabetes duration was 6.893.7 years (6.393.4 years
for males and 7.193.9 years for females). The most
common anti-diabetic agents prescribed for our patients
were metformin alone (38.7%) or in combination with
glimepiride (55.9%), followed by sulfonylureas (5.4%).
Participants were asked to abstain from their oral anti-
diabetic medications during the day of blood sampling.
Patients treated with insulin or using lipid-lowering
drugs during the study, as well as pregnant women,
were excluded from this study. For data collection, we
used a structured questionnaire to get necessary infor-
mation about general habits and a ‘three-day food
diary’ to assess the dietary intake of each patient. The
diaries were analysed using the software program Nutri
Survey for windows 2007, SEAMEO-TROPMED RCCN-
University of Indonesia (results of food diaries will be
published later). Furthermore, a signed informed consent
was obtained from all patients and their treating physi-
cians before starting the study protocol, considering the
ethical approval No. 142 dated 13 February 2013 from
‘the Director of Health and Population of the Wilaya
of Sidi-Bel-Abbes (Algeria) according to Article 25 of
Decree No. 387 of 31 July 2006 about clinical trials’.
Anthropometric measurements
Body weight (in kilograms) was measured using an
electronic balance (TS-2003A: 360 lb, Capacity: 180 kg,
Graduations 0.1 kg) and height (in metres) was mea-
sured with a body meter (Seca 206, Germany; measuring
range 0220 cm, graduation length 1 mm). The BMI
was calculated as weight (kg)/height2 (m2). Patients were
instructed to be lightly dressed and to respect the appro-
priate position for height measurement (gathered feet,
straight body, heels touching the wall, and staring out
the horizon).
WC was measured respecting every single cm with a
measuring tape (maximum 150 cm, graduation length
1 mm). The tape was gently tightened around the patient’s
abdomen roughly at the horizontal line just above the
uppermost lateral border of the ilium, which corresponds
with the line passing through the navel in men and a bit
above in women.
Blood pressure measurement
OMRON M3 Digital Automatic Blood Pressure Monitor
(Omron Healthcare, Ltd. Kyoto, Japan) was used for
calculating morning blood pressure.
Blood sampling and assay methods
For fasting glucose and lipid profiles, venous blood
samples were collected from each patient 12 h after an
overnight fast. We did not get information about the
kind of food taken before the 12 h of fasting. However,
for the postprandial state, blood samples were drawn
2 h after a breakfast meal for glucose and 34 h for
lipid parameters. The usual breakfast meal in 94% of
our patients provides an average of 692.0911.0 kcal [fat:
44.190.4 g (57%); protein: 7.690.1 g (6%); carbohy-
drates 49.490.7 g (38%)].
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Enzymatic colorimetric methods (Spinreact Reagents,
Spain) (11) were used to determine the fasting and the
postprandial serum concentrations of glucose, total cho-
lesterol (TC), high-density lipoprotein cholesterol (HDL-c),
triglycerides (TG), and direct low-density lipoprotein
cholesterol (LDL-c). TC/HDL-c, TG/HDL-c, and LDL-
c/HDL-c ratios were, respectively, calculated for fasting
and postprandial states. The quantitative determination
of apo A-I and apo B was performed using turbidimetric
tests without undergoing a prior fasting period (Spinreact
Reagents, Spain) (12), then the apo B/apoA-I ratio was
calculated.
The HbA1c levels were determined by an ion exchange
resin separation method. Patients were categorised into
three groups: HbA1cB53.01 mmol/mol; HbA1c
53.0180.34 mmol/mol; HbA1c80.34 mmol/mol.
Statistical analysis
All data were processed and analysed by using SPSS 20.0
(Statistical Package for the Social Sciences, IBM Corpora-
tion; Chicago, IL, August 2011). Results are expressed
as means9standard deviations. Student’s t-test was used
for comparing means values and statistical significance
was set at p0.05. Relationships between apolipoprotein
ratios and lipid ratios were studied using Pearson corre-
lation tests and simple linear regression tests with a
confidence interval of 95%.
Results
Table 1 displays the subjects’ characteristics. No difference
between the two genders was observed with respect to
age, diabetes duration, WC, blood pressure, duration of
overweight and/or obesity, and HbA1c levels. A signifi-
cant gender effect was observed for weight, height, and
BMI (pB0.05). Furthermore, a highly significant effect
of gender was noticed for fasting glycaemia but not for
postprandial glucose levels.
The prevalence of overweight, obesity, and abdominal
obesity was more pronounced in females than in males,
whereas the prevalence of normal weight was higher in
male patients (43.02%) as compared to female patients
(22.36%).
Our results about risk factors and lifestyle showed
that 34.9% of men were current cigarette smokers (we
considered subjects who reported smoking cigarettes
regularly during the year before the survey to be cur-
rent smokers). Women had slightly lower educational
level compared to men (48.02% of women had no formal
education). Regarding the history of family diseases,
diabetes was the most prevalent risk factor for both men
(29.06%) and women (31.57%).
Based on the BMI, in male patients a moderate elevation
of fasting glucose was noted in the normal weight group
(BMIB25 kg/m2) followed by the obese group (BMI]
30 kg/m2) (Table 2). The postprandial glucose level was
rather higher among the overweight group (2.5991.44 g/L)
and the normal weight group (2.4891.17 g/L). However,
in female patients, an elevation of fasting glucose levels was
observed in overweight and obese patients (1.5890.66 vs.
1.5190.62 g/L, respectively). The topmost level of post-
prandial blood glucose was noted in the normal weight
group. There was a highly significant difference between
the fasting and the postprandial glucose levels. Between
genders, a significant difference in fasting glycaemia was
noted for the group of normal weight patients.
On the basis of WC, significant increase of the fast-
ing glycaemia was noted in female patients suffering
from abdominal obesity (1.5290.60 g/L) compared to
those with normal WC (1.3490.39 g/L). In both genders,
abdominal obesity does not seem to be a factor helping to
increase the blood glucose during the postprandial state.
Comparing between the fasting and postprandial states
and except for HDL-c and TG, the lipid values in male
patients did not differ according to the BMI and/or WC
(Table 2). Significantly lower HDL-c levels were obtained
during the postprandial state for BMI25.029.9 kg/m2
and abdominal obesity (WC94 cm). However, TG
levels showed significant increases during the postpran-
dial state with BMI]30 kg/m2 and abdominal obesity.
In contrast, highly significant increases in TC were ob-
served during the postprandial state in female patients
with BMI25.029.9 kg/m2 (pB0.01) and abdominal
obesity (pB0.001). Similarly, in women suffering from
abdominal obesity, postprandial TG levels (1.6590.80
g/L) were significantly higher than fasting levels (1.509
0.78 g/L). The LDL-c level was lower during the post-
prandial state with WC580 cm.
Apolipoproteins (apo A1 and apo B) showed a con-
siderable increase according to BMI and/or WC in both
genders. However, a significant effect of gender differences
was noted on apo A-I in patients with BMI25.029.9
kg/m2 and abdominal obesity (pB0.05).
Table 3 shows the effect of BMI, WC, and HbA1c
level on fasting lipid ratios, postprandial lipid ratios, and
apolipoproteins ratios in type 2 diabetic patients. Among
male patients with BMI2529.9 kg/m2, all lipid ratios
(TC/HDL-c, TG/HDL-c and LDL-c/HDL-c) increased
significantly during the postprandial state compared to
the fasting state. When we compared lipid ratios between
fasting and postprandial states according to WC values,
postprandial TC/HDL-c and TG/HDL-c ratios increased
noticeably in patients with abdominal obesity (WC94 cm).
However, elevated HbA1c levels (]7% or]53.01 mmol/
mol) are more likely to cause an increase in postprandial
ratios of TC/HDL-c and TG/HDL-c. In female patients,
only the TG/HDL-c ratio showed a significant postpran-
dial increase in obese women (BMI]30 kg/m2). Based on
WC, the postprandial TC/HDL-c and TG/HDL-c ratios
were significantly higher than the fasting ratios (Table 3).
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Table 1. Characteristics of the patients
Variables All patients Males Females P value for statistical testa
n 238 86 152 
Age (years), mean9S.D. 57.36911.93 56.84913.11 57.66911.25 0.615
Duration of diabetes (years), mean9S.D. 6.8293.74 6.3393.39 7.1093.90 0.127
Anthropometric characteristics, mean9S.D.
Weight (kg) 75.66913.00 78.59914.28 74.00911.94 0.009
Height (cm) 164.6998.55 171.3997.01 160.8996.85 0.000
Waist circumference (cm) 97.40913.56 95.99912.16 98.20914.28 0.229
BMI (kg/m2) 27.8994.58 26.7394.64 28.5594.44 0.003
Overweight, obesity duration (years) 9.6696.29 10.2596.40 9.3196.25 0.463
Blood pressure, mean9S.D.
Systolic pressure (mmHg) 12.8991.52 12.8791.58 12.9091.49 0.875
Diastolic pressure (mmHg) 7.5990.95 7.6190.94 7.5890.96 0.821
HbA1c (mmol/mol), mean9S.D. 59.45910.05 58.91910.38 59.7899.83 0.280
Fasting glycaemia (g/L), mean9S.D. 1.6090.61 1.7590.62 1.5190.59 0.004
Postprandial glycaemia (g/L), mean9S.D. 2.3191.03 2.4291.15 2.2490.96 0.200
Prevalence of weight categories, n (%)
Normal weight, BMIB25 kg/m2 71 (29.83) 37 (43.02) 34 (22.36) 0.053
Overweight, BMI25.029.9 kg/m2 92 (38.65) 26 (30.23) 66 (43.42) 0.101
Obesity, BMI]30 kg/m2 75 (31.51) 23 (26.74) 52 (34.21) 0.104
Abdominal obesityb 191 (80.25) 50 (58.13) 141 (92.76) 0.028
Educational status, n (%)
Without education 91 (38.23) 18 (20.93) 73 (48.02) 0.050
Primary school 43 (18.06) 18 (20.93) 25 (16.44) 0.182
Middle school 46 (19.32) 25 (29.06) 21 (13.81) 0.118
Secondary school 42 (17.64) 17 (19.76) 25 (16.44) 0.420
Higher education 16 (6.72) 8 (9.30) 8 (5.26) 0.249
Smoking, n (%)
Never 200 (84.03) 48 (55.81) 152 (100) 0.024
Former 8 (3.36) 8 (9.30)  
Current 30 (12.60) 30 (34.88)  
Practice of sports activity, n (%)
Yes 52 (21.84) 31 (36.04) 21 (13.81) 0.361
No 186 (78.15) 55 (63.95) 131 (86.18) 0.193
Family disease history, n (%)
Hypertension 17 (7.14) 5 (5.81) 12 (7.89) 0.371
Overweight, obesity 33 (13.86) 16 (18.60) 17 (1.18) 0.331
Diabetes 73 (30.67) 25 (29.06) 48 (31.57) 0.252
Cardiovascular disease 17 (7.14) 4 (4.65) 13 (8.55) 0.358
All 61 (25.63) 23 (26.74) 38 (25.00) 0.407
No 37 (15.54) 13 (15.11) 24 (15.78) 0.161
Menopausal status, n (%)
Pre-menopause   59 (38.81)
Oestrogen use (yes)   42 (27.63) 
Oestrogen use (no)   17 (11.18) 
Post-menopause   93 (61.18) 
aComparison between males and females; mean values were compared using Student’s t-test. Percentages were compared with
Chi-square test.
bAccording to the International Diabetes Federation (IDF), waist circumference 80 cm for women and 94 cm for men.
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Table 2. Influence of BMI and waist circumference on fasting blood parameters, postprandial blood parameters, and apolipoproteins
Fasting state (g/L) Postprandial state (g/L) Apolipoproteins (g/L)
Variables F Glucose F TC F HDL-c F LDL-c F TG PP Glucose PP TC PP HDL-c PP LDL-c PP TG apo A-I apo B
Males (n86)
Based on BMI
BMIB25 kg/m2 1.8290.71 1.6690.35 0.3590.11 1.0890.38 1.2690.65 2.4891.17*** 1.6890.43 0.3490.12 1.0790.36 1.4990.99 1.1590.44 0.8990.23
BMI25.029.9
kg/m2
1.6390.63 1.6690.33 0.3990.14 1.0590.30 1.2590.55 2.5991.44*** 1.7690.50 0.3290.08* 1.1690.48 1.5991.16 1.1990.34 0.8490.32
BMI]30 kg/m2 1.7990.45 1.7790.42 0.3790.12 1.0790.35 1.3790.64 2.1590.64* 1.7790.46 0.3890.16 1.0790.34 1.6190.79* 1.2990.52 0.9190.33
Based on WC
WC594 cm 1.8390.66 1.6390.34 0.3490.11 1.0790.38 1.1690.54 2.4791.10*** 1.6590.41 0.3390.13 1.0690.34 1.2290.43 1.2090.48 0.8690.23
WC94 cm 1.6990.60 1.7390.37 0.3990.13 1.0690.32 1.3890.65 2.3991.20*** 1.7890.48 0.3590.12* 1.1290.43 1.7991.20* 1.2090.40 0.8990.32
Females (n152)
Based on BMI
BMIB25 kg/m2 1.3890.36# 1.7290.31 0.3990.13 1.1690.29 1.4490.82 2.3090.95*** 1.7890.36 0.3690.10 1.1090.28 1.5890.89 1.2690.27 0.9290.32
BMI25.029.9
kg/m2
1.5890.66 1.6690.36 0.4090.11 1.0490.33 1.4590.72 2.2790.95*** 1.8190.50** 0.4090.12# 1.0890.40 1.6490.92 1.3890.40# 1.0090.52
BMI]30 kg/m2 1.5190.62 1.7290.36 0.4090.10 1.0490.31 1.6090.77 2.1890.99*** 1.8290.39 0.3990.11 1.0790.30 1.7990.63 1.3290.35 1.0390.46
Based on WC
WC580 cm 1.3490.39# 1.8890.43 0.3890.17 1.4390.16# 1.4590.36 2.3490.33* 1.6490.43 0.2890.10 0.9690.28* 1.9991.13## 1.0490.23 0.8290.21
WC80 cm 1.5290.60 1.6890.34 0.4090.10 1.0490.31 1.5090.78 2.2490.95*** 1.8290.43*** 0.4090.11# 1.0990.34 1.6590.80* 1.3590.36# 1.0090.47
BMI: body mass index; WC: waist circumference; F: fasting; PP: postprandial. Asterisks: Significantly different from the identical fasting parameter at *pB0.05, **pB0.01, ***pB0.001.

















































































































The TC/HDL-c ratio was more influenced by a high
level of HbA1c.
Between genders, appreciable lowering of TC/HDL-c,
TG/HDL-c, and LDL-c/HDL-c ratios was observed in
female patients suffering from abdominal obesity; low
TC/HDL-c and LDL-c/HDL-c ratios were also observed
in overweight women (BMI25.029.9 kg/m2). The apo
B/apo A-I ratio did not show any significant difference
between the two genders (Table 3).
As illustrated in Fig. 1, the apo B/apo A-I ratio was
significantly correlated with TC/HDL-c, TG/HDL-c, and
LDL-c/HDL-c ratios both in fasting and in postprandial
states. However, we noticed that the apo B/apo A-I ratio
provides the strongest positive correlations with TC/
HDL-c (pB0.01, r20.321, F111.453) and LDL-c/
HDL-c (pB0.001, r20.300, F103.317) ratios during
the postprandial period.
As depicted in Table 4, we evaluated the risk of
myocardial infarction in our diabetic patients in terms
of increased apo B/apo A-I ratio. Tentative risk zones used
in this table are based on cut-off values adapted from
the Apolipoprotein-related Mortality Risk (AMORIS)
(13) and INTERHEART (14) studies. For men, the
proportion of patients who were likely to be exposed to
a moderate or high risk was 32.6 and 26.7%, respectively.
Contrariwise, for female patients, 37.5% were exposed to a
higher risk of myocardial infarction.
Discussion
Diabetes mellitus is one of the most prevalent chronic
diseases in almost all countries. Between 2010 and 2030,
the number of adults with diagnosed diabetes is expected
to increase by 69% in developing countries and by 20% in
developed countries (1). Concurrently, the prevalence of
obesity is increasing dramatically all over the world (15).
Obesity is medically defined as a state of increased adipose
tissue of a magnitude sufficient to lead to worsening of
all the elements of the metabolic syndrome, namely insulin
resistance, hyperinsulinaemia, dyslipidaemia, and hyper-
tension (2, 16). The classification system for obesity is
Table 3. Variations of apolipoproteins ratio, and fasting and postprandial lipid ratios according to BMI, waist circumference,
and HbA1c level
Fasting state Postprandial state
Apolipoproteins
Variables TC/HDL-c TG/HDL-c LDL-c/HDL-c TC/HDL-c TG/HDL-c LDL-c/HDL-c apo B/apo A-I
Males (n86)
Based on BMI
BMIB25 kg/m2 4.9591.31 3.9592.61 3.1991.25 5.2491.30 4.9493.63 3.3291.12 0.8190.24
BMI25.029.9 kg/m2 4.6391.46 3.5191.72 2.9991.30 5.7592.36* 5.1393.46* 3.8692.14* 0.7590.41
BMI]30 kg/m2 4.9691.63 3.9091.88 3.0591.30 5.0091.63 4.8592.88 3.0491.21 0.7790.30
Based on WC
WC594 cm 5.0591.30 3.8192.46 3.3291.32 5.2491.36 4.1792.48 3.3791.21 0.7790.25
WC94 cm 4.7191.52 3.8191.96 2.9391.21 5.4092.02* 5.5693.78* 3.4491.74 0.7990.35
Based on HbA1c
HbA1cB53.01 mmol/mol 5.0991.57 3.5791.74 3.4191.41 5.1891.23 4.7693.16 3.3591.16 0.8090.19
HbA1c53.0180.34 mmol/mol 4.8391.42 4.0292.30 2.9891.24 5.4392.09* 5.2893.64* 3.4291.79 0.7990.37
HbA1c80.34 mmol/mol 4.1490.73 3.3892.84 2.6290.55 5.2991.28* 3.8691.96 3.5591.08 0.6890.26
Females (n152)
Based on BMI
BMIB25 kg/m2 4.8992.00 4.2292.88 3.3591.65 5.3191.88 5.0894.12 3.2991.26 0.7590.29
BMI25 to 29.9 kg/m2 4.3791.29 3.9192.22 2.7691.05 4.8291.70# 4.4992.95 2.9291.36# 0.7590.36
BMI]30 kg/m2 4.4891.25 4.2392.38 2.7491.07 4.9191.57 4.9292.24* 2.9291.20 0.8190.37
Based on WC
WC580 cm 5.7692.70 4.3891.83 4.4192.02# 6.5792.75# 8.4996.35*## 3.8691.59 0.8190.24
WC80 cm 4.4391.29 4.0692.46 2.7691.07 4.8391.53*# 4.4892.43*# 2.9491.24# 0.7790.36
Based on HbA1c level
HbA1cB53.01 mmol/mol 4.7891.68 4.5292.59 3.0291.41 5.1791.96 5.6294.07* 3.0491.34 0.8190.41
HbA1c53.0180.34 mmol/mol 4.4191.26 3.9392.21 2.8091.06 4.8291.55* 4.3992.31 2.9491.27 0.7490.32
HbA1c80.34 mmol/mol 4.4191.88 3.6893.02 2.9691.62 5.1691.65 4.3892.74 3.2891.27 0.8190.30
BMI: body mass index; WC: waist circumference. *Significantly different from the identical fasting lipid ratio at pB0.05. # and ##:
significantly different from male patients at #pB0.05, ##pB0.01.
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based on BMI as the most frequently used diagnostic tool.
However, the body fat distribution, particularly abdom-
inal fat accumulation, exerts a strong influence on the
development of glucose intolerance and type 2 diabetes
co-morbidities. Several investigators have reported that
individuals with similar BMI but with different WC show
different metabolic risks of diabetes and CVD (17, 18).
In the same context, as reported by Elley et al., HbA1c
is considered as an important indicator of blood glucose
control; an HbA1c ‘threshold’ of 53.01 mmol/mol is
a significantly higher risk of macrovascular disease in
diabetic patients. Every 1% higher HbA1c level above that
threshold is associated with an independent increased
CVD risk (19).
Fig. 1. Mutual association between apolipoproteins ratio and lipid ratios during fasting and postprandial states.
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The purpose of the present study was to establish,
during fasting and postprandial states in type 2 diabetes
patients, the influence of overweight/obesity (defined by
BMI), abdominal obesity (measured by WC), and HbA1c
levels on blood glucose and lipids parameters and dysli-
pidaemia (defined by lipid and apolipoprotein ratios).
Preliminary results from this study indicate some
unfavourable interactions of BMI and WC with the
glucose and individual lipid profiles of diabetic patients
during both fasting and postprandial states. Though the
gender difference in our population has a limited effect
on major metabolic changes, the increase in lipid and
apolipoprotein levels is more pronounced with BMI and
WC during the postprandial state. Our finding shows
that apo B levels exceed the optimal target of 0.9 g/L
(13) and are strongly influenced by BMI and WC in both
genders, thereby indicating a high cardiometabolic risk
in our patients. However, in addition to contributions of
obesity and body fat distribution to the development of
pre-diabetes and type 2 diabetes co-morbidities, obesity
promotes alterations in other intermediate risks in rela-
tion to dyslipidaemia, glucose intolerance, the inflamma-
tory state, as additional unknown mechanisms may vary
between the genders (20, 21). Gender differences regard-
ing the effect of overweight/obesity on metabolic disorder
is likely to result from the influence of several factors,
such as delayed dietary fat clearance, which results from
abdominal adipose tissue accumulation in men, along
with a concomitant decrease in the postprandial meta-
bolism of fatty acids and a decreased ability to store lipids
in subcutaneous adipose tissue (22).
The risk of vascular disease is two- to four-fold greater
in adults with diabetes than among non-diabetic indivi-
duals (23). However, association between diabetes and
risk factors for CVD, such as dyslipidaemia (previously
called hyperlipaemia), hypertension, and hyperinsulinae-
mia, bring out the necessity of an aggressive manage-
ment (24). Therefore, tables of cardiovascular risk (e.g.
the Framingham score or the EuroSCORE) (25, 26) and
international recommendations (e.g. recommendations of
the National Cholesterol Education Program  NCEP,
2001) (27), centred on the classic lipid profile, were
developed to validate the effectiveness of lipid-lowering
therapies. But important limitations of these parameters in
cardiovascular risk prediction have been demonstrated (28).
There is now more evidence from cohort and meta-
analysis studies suggesting that lipid ratios (TC/HDL-c,
TG/HDL-c, and LDL-c/HDL-c) have higher association
with CVD than with individual lipids (2932). On the
contrary, prospective risk studies suggest that the use of
apo B/apo A-I ratio may be a promising and convenient
marker of risk of CVD [e.g. AMORIS study (13),
INTERHEART study (14), EPIC-Norfolk study (33),
and ULSAM study (34)].
The apo A-I, apo B, and apo B/apo A-I ratios have
many advantages that surpass their use compared with
normal lipid parameters and their ratios in predicting
CVD. Apo B reflects the atherogenic side and apo A-I
indicates the anti-atherogenic side. Hence, the apo B/apo
A-I ratio reflects the risk of cardiovascular events (13).
Another important feature is that apolipoproteins con-
centrations are not affected by meals and are slightly
influenced by biological variables, unlike the ordinary
lipid parameters, which fluctuate widely depending on
food intake. Therefore, measurement of apolipoproteins
does not require fasting blood samples (12, 13, 35, 36).
In clinical practice, apolipoproteins A-I and B may be
measured directly in plasma without noticeable interference
with high triglyceride levels using internationally standar-
dised methods that are accurate and precise (12, 37).
The results of this study clearly show, for both genders,
that BMI, WC, and impaired glycaemia (defined by
HbA1c) were proportionally related with the degree of dy-
slipidaemia during both fasting and postprandial states.
During the postprandial stage, the apolipoproteins ratio
(apo B/apo A-I) was more correlated with TC/HDL-c
(r20.321, pB0.01, F111.543) and LDL-c/HDL-c
(r20.300, pB0.001, F103.317) and lightly correlated
with TG/HDL-c (r20.142, pB0.001, F39.756). Similar
results have been presented in other studies (9, 10, 3842).
Although the vast majority of patients with established
type 2 diabetes should be considered at high short-term
risk, the association of diabetes with other risk factors
such as overall and/or visceral obesity and blood glucose
alterations should lead to intensive monitoring and
management of this situation. Our findings indicate that
all TC/HDL-c and LDL-c/HDL-c ratios were beyond the
values of the therapeutic target identified by most authors
(4.0 for TC/HDL-c and 2.5 for LDL-c/HDL-c) (43, 44),
which reflects a high risk of CVD in all patients. Values for
Table 4. Risk of myocardial infarction in terms of increased apo B/apo A-I ratio in the studied cases
Low risk Moderate risk High risk
Men apo B/apo A-I ratio 0.40 0.69 0.70 0.89 0.90 1.10
Prevalence, n (%) 35 (40.69) 28 (32.55) 23 (26.74)
Women apo B/apo A-I ratio 0.30 0.59 0.60 0.79 0.80 1.00
Prevalence, n (%) 45 (29.60) 50 (32.89) 57 (37.50)
Adapted with thresholds of AMORIS and INTERHEART studies.
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the apo B/apo A-I ratio during therapy should preferably
be reduced to B0.7 or even lower in patients with great
risk (45). After adapting our data with the risk ranges
of AMORIS and INTERHEART studies (13, 14), we
found that women are more prone to cardiovascular risk
(myocardial infarction) than men in terms of increased
apo B/apo A1 ratio.
One limitation of the present study is the short
postprandial time (34 h), because changes may affect
lipid profiles beyond that time. The effect of age differences
and genetic variations between the two genders is another
limitation; variations in genes such as those encoding
apolipoproteins A1 and B may directly affect postprandial
lipaemia due to their involvement in lipid metabolism.
Finally, information about what each participant had
eaten for breakfast before blood sampling was based on
self-declaration of the patients themselves.
In conclusion, most patients with type 2 diabetes,
whether male or female, have dyslipidaemia to varying
degrees. Dyslipidaemia, one of the CVD risk factors,
becomes more severe with higher BMI and/or WC and
with increased levels of HbA1c. BMI coupled with WC is
more predictive of cardiovascular risk than each body
parameter separately.
Compared with individual lipid parameters, the changes
in lipid ratios could reflect impaired lipid metabolism
at earlier stages. However, lipid ratios are often influenced
by food intake, which could make interpretation of the
results more difficult depending on the fasting or post-
prandial state. There are now a number of user-friendly
reasons for replacing traditional lipids and their ratios
with measures of apo B and apo A-I and their ratio in
clinical practice. As apolipoproteins can be analysed in
non-fasting samples, this is of great practical advantage
for patients and doctors. In addition, it is very helpful to
use a single ratio for risk prediction instead of referring to a
larger number of lipid ratios.
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